Long Term Safety of Immediate-release Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease
A Phase 3b, Multi-center, Open-label Trial to Evaluate the Long Term Safety of Immediate-release Tolvaptan (OPC-41061, 30 mg to 120 mg/Day, Split Dose) in Subjects With Autosomal Dominant Polycystic Kidney Disease
1 other identifier
interventional
1,803
20 countries
210
Brief Summary
The purpose of the trial was to evaluate and describe the long term safety of tolvaptan in participants with autosomal dominant polycystic kidney disease (ADPKD).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_3
Started Oct 2014
Typical duration for phase_3
210 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 25, 2014
CompletedFirst Posted
Study publicly available on registry
September 29, 2014
CompletedStudy Start
First participant enrolled
October 17, 2014
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 9, 2018
CompletedStudy Completion
Last participant's last visit for all outcomes
November 9, 2018
CompletedResults Posted
Study results publicly available
November 27, 2019
CompletedNovember 27, 2019
November 1, 2019
4.1 years
September 25, 2014
November 7, 2019
November 7, 2019
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Number Of Participants Reporting Treatment-Emergent Adverse Events (TEAEs)
An adverse event (AE) was as any untoward medical occurrence associated with the use of an investigational medicinal product (IMP), whether or not considered IMP related. A TEAE was an AE that started after trial drug treatment; or if the event was continuous from baseline and was serious, related to IMP, or resulted in death, discontinuation, interruption or reduction of trial therapy. A serious TEAE included any event that resulted in: death, life-threatening, persistent or significant incapacity, substantial disruption of ability to conduct normal life functions, required inpatient hospitalization, prolonged hospitalization, congenital anomaly/birth defect, or other medically significant events as per medical judgment, that jeopardized the participant and that required medical or surgical intervention. A severe TEAE was an inability to work or perform normal daily activity. A summary of serious and all other non-serious TEAEs, regardless of causality, is located in the AE section.
Baseline through end of treatment (up to 42 months) and follow-up 7 days posttreatment(+ 7 days)
Study Arms (1)
Tolvaptan
EXPERIMENTALTolvaptan was self-administered orally as split-dose regimens. The dose regimens used in this trial were 15/15 milligram (mg), 30/15 mg, 45/15 mg, 60/30 mg, or 90/30 mg. Starting doses were dependent upon the participant's previous trial as follows: * Trial 156-13-210: initiated on tolvaptan at a split-dose of 45/15 mg with upward titration every 3 to 4 days to 60/30 mg or 90/30 mg per day according to tolerability. * Trial 156-08-271: retained the last dose level of tolvaptan received in the trial (45/15 mg, 60/30 mg, or 90/30 mg) and started at that same dose in Trial 156-13-211. * Other Trials (156-04-251 and 156-09-290): initiated on tolvaptan at a split-dose of 45/15 mg with upward titration every 3 to 4 days to 60/30 mg or 90/30 mg per day according to tolerability.
Interventions
Tolvaptan tablets (15 or 30 mg) self-administered orally as split-dose regimens, once upon awakening and another approximately 8 to 9 hours later
Eligibility Criteria
You may qualify if:
- Male and female participants ≥ 18 years with confirmed diagnosis of ADPKD (during participation in prior tolvaptan trials) who have completed and transferred from the double-blind Trial 156-13-210 (12-month period including post treatment follow-up, regardless of whether this was on-treatment or off-treatment), or completed Trial 156-08-271 or a prior tolvaptan trial, or interrupted or discontinued treatment in a prior tolvaptan ADPKD trial other than Trial 156-13-210. Participants may be enrolled with the medical monitor approval, and additional close monitoring may be required at the beginning of the trial.
- eGFR ≥ 20 milliliter (mL)/minute (min)/1.73 meter squared (m\^2) within 3 months prior to the baseline visit. Participants who have an eGFR ≤ 20 mL/min/1.73 m\^2 may be enrolled with medical monitor approval.
You may not qualify if:
- Need for chronic diuretic use
- Hepatic impairment based on liver function abnormalities other than that expected for ADPKD with cystic liver disease
- Women of childbearing potential who do not agree to practice 2 different methods of birth control or remain abstinent during the trial and for 30 days after the last dose of investigational medicinal product (IMP)
- Women who are breast-feeding and/or who have a positive pregnancy test result prior to receiving IMP.
- Participants with contraindications to required trial assessments (contraindications to optional assessments, for example, magnetic resonance imaging \[MRI\] are not a limitation).
- Participants who in the opinion of the investigator or the medical monitor, have a medical history or medical finding inconsistent with safety or trial compliance
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (210)
Unknown Facility
Birmingham, Alabama, 35233, United States
Unknown Facility
Huntsville, Alabama, 35805, United States
Unknown Facility
Mobile, Alabama, 36617, United States
Unknown Facility
Phoenix, Arizona, 85381, United States
Unknown Facility
Tempe, Arizona, 85284, United States
Unknown Facility
Tucson, Arizona, 85745, United States
Unknown Facility
La Jolla, California, 92037, United States
Unknown Facility
Los Angeles, California, 90022, United States
Unknown Facility
Los Angeles, California, 90095, United States
Unknown Facility
San Francisco, California, 94143, United States
Unknown Facility
Stanford, California, 94305, United States
Unknown Facility
Aurora, Colorado, 80045, United States
Unknown Facility
Denver, Colorado, 80204, United States
Unknown Facility
Denver, Colorado, 80210, United States
Unknown Facility
New Haven, Connecticut, 06520, United States
Unknown Facility
Hudson, Florida, 34667, United States
Unknown Facility
Jacksonville, Florida, 32216, United States
Unknown Facility
Miami, Florida, 33150, United States
Unknown Facility
Ocala, Florida, 34471, United States
Unknown Facility
Port Charlotte, Florida, 33952, United States
Unknown Facility
Tampa, Florida, 33614, United States
Unknown Facility
Atlanta, Georgia, 30322, United States
Unknown Facility
Augusta, Georgia, 30909, United States
Unknown Facility
Meridian, Idaho, 83642, United States
Unknown Facility
Chicago, Illinois, 60611, United States
Unknown Facility
Chicago, Illinois, 60637, United States
Unknown Facility
Kansas City, Kansas, 66160, United States
Unknown Facility
Wichita, Kansas, 67214, United States
Unknown Facility
Baton Rouge, Louisiana, 70808, United States
Unknown Facility
Baltimore, Maryland, 21201, United States
Unknown Facility
Baltimore, Maryland, 21224, United States
Unknown Facility
Greenbelt, Maryland, 20770, United States
Unknown Facility
Rockville, Maryland, 20850, United States
Unknown Facility
Boston, Massachusetts, 02111, United States
Unknown Facility
Springfield, Massachusetts, 01107, United States
Unknown Facility
Detroit, Michigan, 48202, United States
Unknown Facility
Grand Rapids, Michigan, 49506, United States
Unknown Facility
Kalamazoo, Michigan, 49007, United States
Unknown Facility
Pontiac, Michigan, 48341, United States
Unknown Facility
Roseville, Michigan, 48066, United States
Unknown Facility
Rochester, Minnesota, 55905, United States
Unknown Facility
St Louis, Missouri, 63110, United States
Unknown Facility
Las Vegas, Nevada, 89106, United States
Unknown Facility
Reno, Nevada, 89511, United States
Unknown Facility
Eatontown, New Jersey, 07724, United States
Unknown Facility
Voorhees Township, New Jersey, 08043, United States
Unknown Facility
Buffalo, New York, 14219, United States
Unknown Facility
Laurelton, New York, 11413, United States
Unknown Facility
Mineola, New York, 11501, United States
Unknown Facility
New York, New York, 10021, United States
Unknown Facility
New York, New York, 10032, United States
Unknown Facility
Asheville, North Carolina, 28801, United States
Unknown Facility
Chapel Hill, North Carolina, 27599, United States
Unknown Facility
Charlotte, North Carolina, 28207, United States
Unknown Facility
Winston-Salem, North Carolina, 27103, United States
Unknown Facility
Fargo, North Dakota, 58102, United States
Unknown Facility
Akron, Ohio, 44302, United States
Unknown Facility
Cincinnati, Ohio, 45206, United States
Unknown Facility
Cincinnati, Ohio, 45229, United States
Unknown Facility
Cleveland, Ohio, 44106, United States
Unknown Facility
Columbus, Ohio, 43210, United States
Unknown Facility
Portland, Oregon, 97210, United States
Unknown Facility
Bethlehem, Pennsylvania, 18017, United States
Unknown Facility
Doylestown, Pennsylvania, 18901, United States
Unknown Facility
Philadelphia, Pennsylvania, 19104, United States
Unknown Facility
Charleston, South Carolina, 29425, United States
Unknown Facility
Columbia, South Carolina, 29203, United States
Unknown Facility
Orangeburg, South Carolina, 29118, United States
Unknown Facility
Knoxville, Tennessee, 37923, United States
Unknown Facility
Nashville, Tennessee, 37205, United States
Unknown Facility
Nashville, Tennessee, 37232, United States
Unknown Facility
Arlington, Texas, 76015, United States
Unknown Facility
Houston, Texas, 77004, United States
Unknown Facility
Houston, Texas, 77030, United States
Unknown Facility
McAllen, Texas, 78503, United States
Unknown Facility
Burlington, Vermont, 05401, United States
Unknown Facility
Arlington, Virginia, 22207, United States
Unknown Facility
Charlottesville, Virginia, 22908, United States
Unknown Facility
Norfolk, Virginia, 23507, United States
Unknown Facility
Wenatchee, Washington, 98801, United States
Unknown Facility
Morgantown, West Virginia, 26506, United States
Unknown Facility
Ciudad Autonoma de Buenos Aires, Buenos Aires, C1093AAS, Argentina
Unknown Facility
Ciudad Autonoma de Buenos Aires, Buenos Aires, C1425APQ, Argentina
Unknown Facility
Ciudad Autonoma de Buenos Aires, Buenos Aires, C1429BWN, Argentina
Unknown Facility
Ciudad Autonoma de Buenos Aires, Buenos Aires, C1431FWO, Argentina
Unknown Facility
Junín, Buenos Aires, 6000, Argentina
Unknown Facility
Pergamino, Buenos Aires, B2700CPM, Argentina
Unknown Facility
Pilar, Buenos Aires, B1629ODT, Argentina
Unknown Facility
Córdoba, X5000JHQ, Argentina
Unknown Facility
Córdoba, X5016KEH, Argentina
Unknown Facility
Córdoba, X5166BPW, Argentina
Unknown Facility
Camperdown, New South Wales, 2050, Australia
Unknown Facility
New Lambton Heights, New South Wales, 2305, Australia
Unknown Facility
St Leonards, New South Wales, 2065, Australia
Unknown Facility
Westmead, New South Wales, 2145, Australia
Unknown Facility
Woolloongabba, Queensland, 4102, Australia
Unknown Facility
Adelaide, South Australia, 5000, Australia
Unknown Facility
Launceston, Tasmania, 7250, Australia
Unknown Facility
Parkville, Victoria, 3050, Australia
Unknown Facility
Reservoir, Victoria, 3073, Australia
Unknown Facility
Richmond, Victoria, 3121, Australia
Unknown Facility
Perth, Western Australia, 6000, Australia
Unknown Facility
Aalst, 9300, Belgium
Unknown Facility
Brussels, 1090, Belgium
Unknown Facility
Brussels, 1200, Belgium
Unknown Facility
Edegem, 2650, Belgium
Unknown Facility
Ghent, 9000, Belgium
Unknown Facility
Kortrijk, 8500, Belgium
Unknown Facility
Leuven, 3000, Belgium
Unknown Facility
Liège, 4000, Belgium
Unknown Facility
Edmonton, Alberta, T6G 2B7, Canada
Unknown Facility
Mount Pearl, Newfoundland and Labrador, A1N 3J5, Canada
Unknown Facility
Scarborough Village, Ontario, M1H 3G4, Canada
Unknown Facility
Toronto, Ontario, M4C 5T2, Canada
Unknown Facility
Toronto, Ontario, M5G 2N2, Canada
Unknown Facility
Montreal, Quebec, H4J 1C5, Canada
Unknown Facility
Brno, 625 00, Czechia
Unknown Facility
České Budějovice, 370 87, Czechia
Unknown Facility
Hradec Králové, 500 05, Czechia
Unknown Facility
Jihlava, 586 01, Czechia
Unknown Facility
Jilemnice, 51401, Czechia
Unknown Facility
Liberec, 460 63, Czechia
Unknown Facility
Ostrava, 708 52, Czechia
Unknown Facility
Prague, 128 08, Czechia
Unknown Facility
Prague, 140 21, Czechia
Unknown Facility
Aalborg, 9100, Denmark
Unknown Facility
Aarhus N, 8200, Denmark
Unknown Facility
Holstebro, 7500, Denmark
Unknown Facility
Heidelberg, Baden-Wurttemberg, 69120, Germany
Unknown Facility
Munich, Bavaria, 81675, Germany
Unknown Facility
Nuremberg, Bavaria, 90471, Germany
Unknown Facility
Wiesbaden, Hesse, 65191, Germany
Unknown Facility
Düsseldorf, North Rhine-Westphalia, 40210, Germany
Unknown Facility
Essen, North Rhine-Westphalia, 45147, Germany
Unknown Facility
Dresden, Saxony, 01307, Germany
Unknown Facility
Berlin, 10117, Germany
Unknown Facility
Budapest, 1032, Hungary
Unknown Facility
Pécs, 7623, Hungary
Unknown Facility
Szeged, 6720, Hungary
Unknown Facility
Ashkelon, 78278, Israel
Unknown Facility
Jerusalem, 9112001, Israel
Unknown Facility
Nahariya, 2210001, Israel
Unknown Facility
Petah Tikva, 491004, Israel
Unknown Facility
Ramat Gan, 52621, Israel
Unknown Facility
Tel Aviv, 6423906, Israel
Unknown Facility
Montichiari, Brescia, 25018, Italy
Unknown Facility
Bari, 70124, Italy
Unknown Facility
Lecco, 23900, Italy
Unknown Facility
Milan, 20122, Italy
Unknown Facility
Milan, 20132, Italy
Unknown Facility
Modena, 41124, Italy
Unknown Facility
Napoli, 80138, Italy
Unknown Facility
Pavia, 27100, Italy
Unknown Facility
Amsterdam, 1081 HV, Netherlands
Unknown Facility
Groningen, 9713 GZ, Netherlands
Unknown Facility
Nijmegen, 6525 GA, Netherlands
Unknown Facility
Bergen, 5021, Norway
Unknown Facility
Ciechanów, 06-400, Poland
Unknown Facility
Gdansk, 80-952, Poland
Unknown Facility
Golub-Dobrzyń, 87-400, Poland
Unknown Facility
Krakow, 31-559, Poland
Unknown Facility
Lodz, 92-213, Poland
Unknown Facility
Lodz, 93-347, Poland
Unknown Facility
Lublin, 20-954, Poland
Unknown Facility
Szczecin, 70-111, Poland
Unknown Facility
Warsaw, 04-749, Poland
Unknown Facility
Wroclaw, 50-556, Poland
Unknown Facility
Bucharest, 010731, Romania
Unknown Facility
Bucharest, 011794, Romania
Unknown Facility
Bucharest, 022328, Romania
Unknown Facility
Oradea, 410469, Romania
Unknown Facility
Kemerovo, 650002, Russia
Unknown Facility
Krasnoyarsk, 660062, Russia
Unknown Facility
Saint Petersburg, 19401344, Russia
Unknown Facility
Saint Petersburg, 197022, Russia
Unknown Facility
Yaroslavl, 150062, Russia
Unknown Facility
Pretoria, Gauteng, 0002, South Africa
Unknown Facility
Durban, KwaZulu-Natal, 4001, South Africa
Unknown Facility
Cape Town, Western Cape, 7925, South Africa
Unknown Facility
Barcelona, 08907, Spain
Unknown Facility
Ciudad Real, 13005, Spain
Unknown Facility
Madrid, 28041, Spain
Unknown Facility
Madrid, 28046, Spain
Unknown Facility
Valencia, 46017, Spain
Unknown Facility
Gothenburg, 413 45, Sweden
Unknown Facility
Linköping, 58185, Sweden
Unknown Facility
Stockholm, 14186, Sweden
Unknown Facility
Stockholm, 17176, Sweden
Unknown Facility
Uppsala, 75185, Sweden
Unknown Facility
Belfast, County Antrim, BT9 7AB, United Kingdom
Unknown Facility
Exeter, Devon, EX2 5DW, United Kingdom
Unknown Facility
Hull, East Riding Of Yorkshire, HU3 2JZ, United Kingdom
Unknown Facility
Brighton, East Sussex, BN2 5BE, United Kingdom
Unknown Facility
London, Greater London, NW3 2QG, United Kingdom
Unknown Facility
London, Greater London, SE5 9RS, United Kingdom
Unknown Facility
London, Greater London, SW17 0QT, United Kingdom
Unknown Facility
Manchester, Greater Manchester, M13 9WL, United Kingdom
Unknown Facility
Salford, Greater Manchester, M6 8HD, United Kingdom
Unknown Facility
Stevenage, Hertfordshire, SG1 4AB, United Kingdom
Unknown Facility
Inverness, Highland Region, IV2 3UJ, United Kingdom
Unknown Facility
Leicester, Leicestershire, LE5 4PW, United Kingdom
Unknown Facility
Edinburgh, Lothian Region, EH16 4SA, United Kingdom
Unknown Facility
Liverpool, Norfolk, L7 8XP, United Kingdom
Unknown Facility
Sheffield, South Yorkshire, S5 7AU, United Kingdom
Unknown Facility
Stoke-on-Trent, Staffordshire, ST4 7LN, United Kingdom
Unknown Facility
Newcastle upon Tyne, Tyne & Wear, NE7 7DN, United Kingdom
Unknown Facility
Coventry, Warwickshire, CV2 2DX, United Kingdom
Unknown Facility
Birmingham, West Midlands, B15 2GW, United Kingdom
Unknown Facility
Middlesbrough, TS4 3BW, United Kingdom
Unknown Facility
Swansea, SA6 6NL, United Kingdom
Related Publications (3)
Chebib FT, Zhou X, Garbinsky D, Davenport E, Nunna S, Oberdhan D, Fernandes A. Tolvaptan and Kidney Function Decline in Older Individuals With Autosomal Dominant Polycystic Kidney Disease: A Pooled Analysis of Randomized Clinical Trials and Observational Studies. Kidney Med. 2023 Apr 14;5(6):100639. doi: 10.1016/j.xkme.2023.100639. eCollection 2023 Jun.
PMID: 37250503DERIVEDAlpers DH, Lewis JH, Hunt CM, Freston JW, Torres VE, Li H, Wang W, Hoke ME, Roth SE, Westcott-Baker L, Estilo A. Clinical Pattern of Tolvaptan-Associated Liver Injury in Trial Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD): An Analysis of Pivotal Clinical Trials. Am J Kidney Dis. 2023 Mar;81(3):281-293.e1. doi: 10.1053/j.ajkd.2022.08.012. Epub 2022 Sep 30.
PMID: 36191725DERIVEDTorres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Lee J, Hoke ME, Estilo A, Sergeyeva O. Multicenter Study of Long-Term Safety of Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease. Clin J Am Soc Nephrol. 2020 Dec 31;16(1):48-58. doi: 10.2215/CJN.10250620. Epub 2020 Dec 29.
PMID: 33376102DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Results Point of Contact
- Title
- Global Clinical Development
- Organization
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Publication Agreements
- PI is Sponsor Employee
- No
- Restriction Type
- OTHER
- Restrictive Agreement
- Yes
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 25, 2014
First Posted
September 29, 2014
Study Start
October 17, 2014
Primary Completion
November 9, 2018
Study Completion
November 9, 2018
Last Updated
November 27, 2019
Results First Posted
November 27, 2019
Record last verified: 2019-11
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP, CSR
- Time Frame
- Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.
- Access Criteria
- Otsuka will share data on an Otsuka-owned remotely accessible data sharing platform with Python and R analytical software. Research requests should be directed to clinicaltransparency@Otsuka-us.com
Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.